Oakworth Capital’s Bio-Rad Laboratories Class A BIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.05K | Hold |
24
| – | – | ﹤0.01% | 735 |
|
|
2026
Q1 | $6.69K | Hold |
24
| – | – | ﹤0.01% | 701 |
|
|
2025
Q4 | $7.27K | Buy |
24
+14
| +140% | +$4.37K | ﹤0.01% | 688 |
|
|
2025
Q3 | $2.8K | Hold |
10
| – | – | ﹤0.01% | 734 |
|
|
2025
Q2 | $2.41K | Hold |
10
| – | – | ﹤0.01% | 564 |
|
|
2025
Q1 | $2.44K | Hold |
10
| – | – | ﹤0.01% | 603 |
|
|
2024
Q4 | $3.29K | Hold |
10
| – | – | ﹤0.01% | 565 |
|
|
2024
Q3 | $3.35K | Sell |
10
-5
| -33% | -$1.59K | ﹤0.01% | 590 |
|
|
2024
Q2 | $4.1K | Hold |
15
| – | – | ﹤0.01% | 596 |
|
|
2024
Q1 | $5.19K | Hold |
15
| – | – | ﹤0.01% | 529 |
|
|
2023
Q4 | $4.84K | Buy |
15
+5
| +50% | +$1.57K | ﹤0.01% | 550 |
|
|
2023
Q3 | $3.58K | Sell |
10
-19
| -66% | -$7.33K | ﹤0.01% | 525 |
|
|
2023
Q2 | $11K | Buy |
29
+19
| +190% | +$7.73K | ﹤0.01% | 449 |
|
|
2023
Q1 | $4.79K | Hold |
10
| – | – | ﹤0.01% | 502 |
|
|
2022
Q4 | $4.21K | Hold |
10
| – | – | ﹤0.01% | 496 |
|
|
2022
Q3 | $4K | Hold |
10
| – | – | ﹤0.01% | 504 |
|
|
2022
Q2 | $5K | Hold |
10
| – | – | ﹤0.01% | 485 |
|
|
2022
Q1 | $6K | Hold |
10
| – | – | ﹤0.01% | 480 |
|
|
2021
Q4 | $8K | Hold |
10
| – | – | ﹤0.01% | 495 |
|
|
2021
Q3 | $7K | Hold |
10
| – | – | ﹤0.01% | 493 |
|
|
2021
Q2 | $6K | Hold |
10
| – | – | ﹤0.01% | 505 |
|
|
2021
Q1 | $6K | Hold |
10
| – | – | ﹤0.01% | 493 |
|
|
2020
Q4 | $6K | Hold |
10
| – | – | ﹤0.01% | 470 |
|
|
2020
Q3 | $5K | Hold |
10
| – | – | ﹤0.01% | 482 |
|
|
2020
Q2 | $5K | Hold |
10
| – | – | ﹤0.01% | 463 |
|
|
2020
Q1 | $4K | Hold |
10
| – | – | ﹤0.01% | 439 |
|
|
2019
Q4 | $4K | Hold |
10
| – | – | ﹤0.01% | 481 |
|
|
2019
Q3 | $3K | Hold |
10
| – | – | ﹤0.01% | 502 |
|
|
2019
Q2 | $3K | Hold |
10
| – | – | ﹤0.01% | 553 |
|
|
2019
Q1 | $3K | Hold |
10
| – | – | ﹤0.01% | 518 |
|
|
2018
Q4 | $2K | Hold |
10
| – | – | ﹤0.01% | 534 |
|
|
2018
Q3 | $3K | Hold |
10
| – | – | ﹤0.01% | 535 |
|
|
2018
Q2 | $3K | Hold |
10
| – | – | ﹤0.01% | 559 |
|
|
2018
Q1 | $3K | Hold |
10
| – | – | ﹤0.01% | 538 |
|
|
2017
Q4 | $3K | Hold |
10
| – | – | ﹤0.01% | 541 |
|
|
2017
Q3 | $2K | Hold |
10
| – | – | ﹤0.01% | 574 |
|
|
2017
Q2 | $2K | Hold |
10
| – | – | ﹤0.01% | 568 |
|
|
2017
Q1 | $2K | Hold |
10
| – | – | ﹤0.01% | 573 |
|
|
2016
Q4 | $2K | Buy |
+10
| New | +$1.71K | ﹤0.01% | 580 |
|
Other funds holding BIO
AI
Oakworth Capital's BIO Position: Q2 2026 in Review
Oakworth Capital held its Bio-Rad Laboratories Class A (BIO) position steady in Q2 2026 at 24 shares worth $7.05K. The position accounts for ﹤0.01% of the portfolio, ranked #735.
Oakworth Capital first reported a position in BIO in Q4 2016 and has held it in 39 quarters since. The position peaked at $11K in Q2 2023. 400 funds tracked by Wall St. Rank hold BIO as of Q2 2026.
- Oakworth Capital held 24 shares of Bio-Rad Laboratories Class A worth $7.05K as of Q2 2026.
- Oakworth Capital left its Bio-Rad Laboratories Class A share count unchanged in Q2 2026.
- Bio-Rad Laboratories Class A made up ﹤0.01% of Oakworth Capital's portfolio in Q2 2026, its #735 holding.
- Oakworth Capital first reported a position in Bio-Rad Laboratories Class A in Q4 2016 and has held it in 39 quarters since.
- Oakworth Capital's Bio-Rad Laboratories Class A position peaked at $11K in Q2 2023.
- 400 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.
Based on Oakworth Capital's 13F filing for Q2 2026, filed 22 Jul 2026.